Letter in response to Levonorgestrel-releasing intrauterine system (Mirena®) and Depot medroxyprogesterone acetate (Depo-Provera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised trial by Wong AYK, Tang LCH, Chin RKH Aust N Z J Obstet Gynaecol 2010; 50 (3): 273-279

Abhijit Basu; Arindam Basu; Basu A; Mano Haran; Haran M; Nair A; Anil K. Nair; Anil Nair

doi:10.1111/j.1479-828x.2010.01240.x

Letter in response to Levonorgestrel-releasing intrauterine system (Mirena®) and Depot medroxyprogesterone acetate (Depo-Provera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised trial by Wong AYK, Tang LCH, Chin RKH Aust N Z J Obstet Gynaecol 2010; 50 (3): 273-279

Abhijit Basu, Arindam Basu, Basu A, Mano Haran, Haran M, Nair A, Anil K. Nair, Anil Nair

The Australian & New Zealand journal of obstetrics & gynaecology · 2011 · vol. 51(1) , pp. 97–98 · doi:10.1111/j.1479-828x.2010.01240.x · PMID:21299520 · W1505628618

Other OA: closed CC0 ⤵ 2 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This letter discusses a randomized trial comparing the levonorgestrel-releasing intrauterine system (Mirena®) and depot medroxyprogesterone acetate (Depo-Provera) for long-term maintenance therapy in patients with moderate and severe endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Levonorgestrel Medroxyprogesterone Acetate Contraceptive Agents, Female Contraceptive Agents, Female Contraceptive Agents, Female Endometriosis Endometriosis Endometriosis Female Female Humans Humans Levonorgestrel Levonorgestrel Medroxyprogesterone Acetate Medroxyprogesterone Acetate Randomized Controlled Trials as Topic Randomized Controlled Trials as Topic Severity of Illness Index

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (8)

Cited by (2)

Source provenance

europepmc: last seen: 2026-10-13T06:10:10.580696+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-10-08T21:08:38.374512+00:00
unpaywall: last seen: 2026-10-12T06:33:14.382917+00:00

License: CC0 · commercial use OK

[1] Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients via openalex

[2] Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial via openalex

[3] New techniques in managing endometriosis via openalex

[4] The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex

[5] Uterine nerve fibre proliferation in advanced endometriosis via openalex

[6] Uterosacral nerve fibre proliferation in parous endometriosis via openalex

[7] W2074845402 via openalex

[8] W2170519509 via openalex